ERBB2 and breast carcinoma: These observations are following an in vitro study of the model of this type of cancer, i.e., SK-BR-3 cells, which showed that semisynthetic derivatives of OA, HIMOXOL, and Br-HIMOLID, could be used to efficiently target HER2-positive breast cancer cells.